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A B S T R A C T
Background and objective: A wide range of adjunct therapies after botulinum toxin administration have
been proposed. The aim of the present paper is to provide an overview of major writings dealing with
adjuvant (non-pharmacological) treatments associated with botulinum toxin for managing spasticity in
order to provide some up-to-date information about the usefulness of the most commonly used
procedures.
Methods: The literature in PubMed was searched with the MeSH terms botulinum toxins, muscle
spasticity, physical therapy modalities, and rehabilitation. The results were limited to studies focusing
on adjuvant treatments associatedwith botulinum toxin formanaging spasticity.We excluded papers on
the use of non-drug treatments for spasticity not associated with botulinum toxin serotype A (BoNT-A)
injection. Relevant literature known to the authors along with this complementary search represented
the basis for this overview of the literature.
Results: Adhesive taping and casting effectively improved the botulinum toxin effect in patients with
upper- and lower-limb spasticity. There is level 1 evidence that casting is better than taping for outcomes
including spasticity, range of motion and gait. However, consensus about their most appropriate timing,
duration, target and material is lacking. In terms of physical modalities combined with botulinum toxin
injection, we found level 1 evidence that extracorporeal shock wave therapy is better than electrical
stimulation for some post-injection outcomes including spasticity and pain. Furthermore, electrical
stimulation of injected muscles might be useful to boost the toxin effect. However, the best stimulation
protocol has not been defined. In addition, we found level 2b evidence that whole-body vibration
therapy might reduce spasticity with cerebral palsy.
Conclusion: Future research in this field should focus on investigating the most appropriate post-
injection treatment protocol for each goal to achieve.
C 2018 Elsevier Masson SAS. All rights reserved.1. Introduction
Spasticity is a common consequence of upper motor-neuron
disorders including stroke, acquired brain injury, spinal cord
injury,multiple sclerosis, and cerebral palsy [1]. It has been defined
as a state of increased muscle tone with exaggerated reflexes* Corresponding author. Neuromotor and Cognitive Rehabilitation Research
Center, Department of Neurosciences, Biomedicine and Movement Sciences,
University of Verona, P.le L.A. Scuro, 10, 37134 Verona, Italy.
E-mail address: alessandro.picelli@univr.it (A. Picelli).
https://doi.org/10.1016/j.rehab.2018.08.004
1877-0657/C 2018 Elsevier Masson SAS. All rights reserved.characterized by a velocity-dependent increase in resistance to
passive movement [2].
Botulinum toxin type A (BoNT-A) has been found effective and
safe for treating focal spasticity [3]. Themajor causes for the loss of
BoNT-A response in patients with focal spasticity are an inade-
quate goal for treatment, inaccurate selection and identification of
the correct muscle for injection, insufficient drug dosages,
inadequate injection technique, development of changes in the
muscle, and formation of neutralizing antibodies [4].
Amultidisciplinary team shouldmanage spasticity, considering
BoNT-A administration as part of an integrated rehabilitation
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BoNT-A injection have been proposed [5–9]. The aim of the present
paper is to provide an overview of major writings dealing with
adjuvant (non-pharmacological) treatments associated with
BoNT-A injection for managing spasticity in order to provide
some up-to-date information about the usefulness of the most
commonly used procedures.
2. Methods
The literature in PubMed was searched with the MeSH terms
botulinum toxins, muscle spasticity, physical therapy modalities,
and rehabilitation. The results were limited to studies focusing on
adjuvant treatments associated with BoNT-A for managing
spasticity. We excluded papers about the use of non-drug
treatments for spasticity not associated with BoNT-A injection.
Relevant literature known to the authors along with this
complementary search represented the basis for this literature
overview [5–8].
3. Results
Several studies reported on adjuvant treatments associated
with BoNT-A for managing spasticity. Results from studies
identified for this literature overview are described.
3.1. Muscle stretching
Muscle stretching includes several procedures that can be
applied by moving the joint through its range of motion (ROM)
manually or with different devices [10]. The goal of stretching
procedures in managing spasticity is to maintain or increase joint
mobility by normalizing muscle tone, improving soft tissue
extensibility, and reducing contracture [8]. Stretching was
hypothesized to increase the extensibility of soft tissues by a
mechanism that involves viscous deformation and structural
adaptations of muscle and other soft tissues such as tendon,
connective, vascular, dermal and neural tissues [1,6,8].
Muscle stretching can be obtained by means of several
procedures, including passive stretching, active stretching, pro-
longed positioning, isotonic stretching, and isokinetic stretching
[8]. Some different features of stretching have been defined:
intensity (amount of tension applied), velocity (speed of elonga-
tion), repetitions (number per session), duration (time of elonga-
tion per repetition), dose (total time of elongation), and frequency
(periodicity of the stretch) [8,11].
There is high-quality evidence that stretching does not have
clinically important effects on joint mobility in people (with or
without neurological conditions) if performed for less than
7 months [10]. Furthermore, from a clinical practice point of
view, some adverse events of stretching procedures have been
reported, including skin breakdown, bruising, blisters and pain
[8,12]. Well-designed studies are needed to better assess the
effects of stretching associated with BoNT-A treatment in patients
with spasticity.
3.2. Taping
Adhesive taping techniques are used for managing spasticity to
obtain a progressive stretch of hypertonic muscles by applying
strips of adhesive tape in order to reach the maximal elongation
[8].
For the upper limb, a case–control study of 65 adults with
stroke found greater reduction ofmuscle hypertonia with adhesive
taping (in place for 6 days and checked daily) than electricalstimulation (ES) of the injected muscles plus splinting in stroke
patients with wrist and finger flexor spasticity treated with BoNT-
A [13]. For the taping protocol, the authors suggested that after the
first application (requiring about 45 min), taping should be
checked daily to maintain the strips firmly pulled and tensioned
(checking requires about 10 min) [13]. More recently, a random-
ized controlled trial (RCT) of 70 stroke patients (PEDro score 8/10)
compared adhesive taping to daily manual muscle stretching
combined with BoNT-A in stroke patients with wrist and finger
flexor spasticity [14]. Spasticity and disability was decreased more
with taping (10 days of application with daily check) (assessed by
the Disability Assessment Scale) than daily sessions of muscle
manual stretching plus passive articular mobilization of wrist and
fingers and splinting [14].
For the lower limb, an RCT of 18 stroke outpatients (PEDro score
5/10) found that ankle-foot taping combined with low-dose BoNT-
A injection into the tibialis posterior muscle was as effective as the
usual BoNT-A injection scheme (several muscles and higher doses)
for treating spastic equinovarus foot in patients with stroke
[15]. An RCT of 23 stroke patients (PEDro score 6/10) compared
taping (maintained for 5 days and checked daily), ES (5 Hz,
rectangular biphasic balanced current stimulation of the injected
muscles for 5 days, 30 min twice a day) and stretching (30 min
stretching of the calf muscles twice a day for 7 days) after BoNT-A
injection at the medial and lateral gastrocnemius muscles in
patients with stroke [16]. Taping and ES groups performed better
on Modified Ashworth scale (MAS) and motor action potential
(MAP) was reduced at 3-month follow-up [16].
An RCT of 20 stroke patients (PEDro score 7/10) compared
kinesiotaping versus sham taping as adjuvant treatment associat-
ed with BoNT-A injection for managing spastic equinus due to
stroke, reporting no clear benefit of kinesiotaping [17]. From a
technical point of view, kinesiotaping differs from usual adhesive
taping. Indeed, the kinesiotaping was applied following 4 steps: (supine) strip placed from the midfoot and attached just below
the fibular head over the tibialis anterior muscle; (prone) strip attached from the heel to each head of the
gastrocnemius muscle; (prone) strip placed at the arch and stretched slightly above both
the medial and lateral malleolus; (prone) strip stretched across the anterior ankle, covering both
the medial and lateral malleolus [17].
3.3. Casting
For managing spasticity, casting should be considered in order
to reduce excitatory input of muscle spindles, preventing changes
in muscle length and reducing contractures [10,18]. Casting is
usually applied to the affected (upper or lower) limb to immobilize
it in a predetermined position with molded casts made of plasters
or tape materials [8,19]. In addition, serial casting allows for
progressively increasing the angle of stretch in order to improve
ROM by changing passive mechanical properties of the muscle and
increasing the number of sarcomeres [20]. It has been proposed as
adjuvant treatment after BoNT-A injection in children with
cerebral palsy and adults with acquired brain injury [21,22]. In
particular, for children with cerebral palsy, delayed serial casting
after BoNT-A injection compared to immediate serial casting had a
significantly better effect on spasticity at 3 and 6 months after
treatment in a pilot study of 12 children (PEDro score 5/10)
[22]. With respect to post-stroke spasticity, a pilot study of
13 stroke patients (PEDro score 5/10) found that Neofrakt1 night
casting may lead to prolonged stretching of spastic muscles with
long-lasting therapeutic benefit due to enhancing the BoNT-A
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patients found significant improvements in ROM and functional
profile after a serial casting program combined with BoNT-A
injection [24]. An RCT (PEDro score 7/10) compared the effect of
taping, casting and stretching after BoNT-A injection in plantar-
flexor muscles of 69 stroke patients with spastic equinus
[25]. Combining BoNT-A with casting or taping may lead to better
and longer lasting effects on spasticity, gait function and ankle
passive ROM (PROM) than stretching procedures alone [25].
3.4. Splinting and orthoses
A splint is a removable device designed to support weak and
ineffective joints or muscles [26]. For managing spasticity,
splinting is mainly based on 2 approaches: the biomechanical
approach, which aims to prevent deformity by aligning, mobilizing
and stabilizing joints, and the neurophysiological approach, which
aims to reduce spasticity by sustained stretch and reflex-inhibiting
positions [8]. Orthoses are orthopedic devices aimed to replace or
substitute for the loss of muscle function; to correct, compensate
or prevent abnormal postures or deformities; and to aid
movements of an injured limb. Orthoses are often used in
conjunction with other interventions such as physical therapy
and/or BoNT-A treatment [27,28]. The literature is sparse on the
use of splinting and orthoses as adjuvant treatment to BoNT-A
injection in patients with spasticity.
A recent case-control study found a significantly greater
reduction of upper-limb spasticity in 39 stroke patients who
received BoNT-A plus (volar-dorsal wrist/hand immobilization)
splinting as compared with BoNT-A or splinting alone [29]. How-
ever, an RCT of 70 stroke patients (PEDro score 8/10) found that
palmar splinting combined with manual stretching and passive
joint mobilization was less effective than adhesive taping for
enhancing the outcome (muscle hypertonia, disability and
position) of BoNT-A treatment in stroke patients with wrist and
finger flexor muscle spasticity [14].
For orthoses, a retrospective chart review found no difference
between 2 small groups of chronic stroke patients in terms of
spasticity when using a dynamic wrist-hand orthosis combined or
not with BoNT-A injection in the spastic upper limb [30]. Con-
versely, a case-control study of 103 stroke patients reported that
(color Doppler) ultrasound-guided BoNT-A injection combined
with ankle foot orthosis might effectively reduce muscle spasm
and thus promote movement, balance and daily life activities [31].
3.5. Physical modalities
The usefulness of physical modalities as adjuvant treatments
formanaging spasticity has beenwidely described in the literature.
This section reports the antispastic effects of extracorporeal shock
wave therapy (ESWT), therapeutic ultrasound (US), vibration
therapy (VT), ES, and transcutaneous electrical nerve stimulation
(TENS).
3.5.1. Extracorporeal shock wave therapy (ESWT)
ESWT is defined as a sequence of single sonic pulses
characterized by high peak pressure (100 MPa), fast pressure rise
(< 10 ns), and short duration (10 ms) conveyed by an appropriate
generator to a specific target area with an energy density from
0.003 to 0.890 mJ/mm2 [8]. Radial ESWT uses a type of
pneumatically generated shock wave with low to medium energy
that disperses eccentrically from the applicator tip without
focusing the energy on a targeted spot [32,33].
ESWT is thought to produce a ‘‘neurological’’ effect on spastic
muscles by inducing enzymatic and non-enzymatic nitric oxidesynthesis, which allows for modulation of neurotransmission at
the neuromuscular junctions [34]. Nitric oxide is involved in
neuromuscular junction formation at the peripheral nervous
system and in essential physiological functions of the central
nervous system, including neurotransmission, memory, and
synaptic plasticity [34,35]. In addition, ESWT has been suggested
to have a direct ‘‘non-neural rheological’’ effect on hypertonic
muscles in terms of the documented therapeutic effects of shock
waves on bone and tendon diseases [35]. Both focused and radial
ESWT were recently found to similarly improve spasticity of the
gastrocnemius muscle in patients with stroke [36].
3.5.2. Therapeutic ultrasound (US)
According to its thermal (deep heat) and mechanical effects, US
has been reported to lead to increased local metabolism, blood
flow, extensibility of connective tissue and tissue regeneration at
the target tissues [37,38]. For healthy muscles, US combined with
stretching significantly improved the extensibility of muscular
tissue as compared with static stretch only [39]. For spastic
muscles, US may allow for changes of viscoelastic properties and
also decrease the sensitivity of the muscle spindle to stretch and
alpha motoneuron excitability by increasing the tissue tempera-
ture [37,38]. This reasoning comes from 2 small-sample studies
(PEDro score 5/10) finding a significant reduction in alpha
motoneuron excitability (as measured by Hmax/Mmax ratio)
and ankle plantar flexor spasticity (measured by the MAS) in
patients with post-stroke spasticity after fifteen 10-min sessions of
continuous US (intensity 1.5 W/cm2) [37,38]. Unfortunately, the
antispastic effect of US was not further confirmed by subsequent
studies. First, a cross-sectional study (PEDro score 4/10) comparing
the efficacy of US and infrared therapy for managing spasticity
found that neither infrared therapy nor US could modify the
clinical and electrophysiological features of spasticity [40]. Fur-
thermore, an RCT of 50 patients with post-stroke spasticity (PEDro
score 6/10) reported no adjuvant effect of continuous US (intensity
1.5 W/cm2) on passive muscle stretching in minimizing spasticity
of the ankle plantar flexors [41]. Finally, a pilot RCT (PEDro score
6/10) found no significant effect of continuous US (intensity
1.5 W/cm2) on spasticity (measured by theMAS) and ankle passive
ROM in 30 patients with spastic equinus due to chronic stroke [42].
3.5.3. Vibration therapy (VT)
Vibratory stimulus modulates primary (Ia) afferent-motoneu-
ron synaptic transmission by inducing presynaptic inhibition
[43]. In whole-body VT, the vibratory stimulus is delivered to the
whole body from the feet, which contact the vibration platform
(static or dynamic exercises are usually performed while standing
on the platform) [44]. Whole-body VT has been found to depress
the H-reflex, increase the excitability of corticomotor pathways
and intracortical inhibition while decreasing intracortical facilita-
tion, and increase temperature and blood flow in both skin and
lower-limbmuscles [45]. In terms ofmuscle spasticity with central
nervous system disorders, a recent systematic review found
insufficient evidence to support (or refute) the use of whole-body
vibration in patientswith stroke, spinocerebellar ataxia ormultiple
sclerosis [45]. In terms of duration, only one study of children with
cerebral palsy reported that an 8-week intervention normalized
muscle tone, improved active joint range and enhanced ambula-
tory performance for at least 3 days [46].
Focal muscle vibration preferentially activates primary (Ia)
spindle afferents, thereby inhibiting the monosynaptic reflex
[47]. Hence, focal VT has been proposed as a potential therapy for
spasticity. In particular, focal VT was found effective in reducing
upper- and lower-limb spasticity in adult patients and lower-limb
spasticity in children with cerebral palsy [48–53].
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addition of segmental muscle VT to BoNT-A injection (as compared
with VT or BoNT-A alone) might lead to further advantages, mostly
in terms of prolonging the effect on muscle tone over time in
patients with multiple sclerosis and spasticity [54].
3.5.4. Electrical stimulation (ES)
Previous studies found that ES might enhance the BoNT-A
neuromuscular blockade effect by increasing and accelerating the
BoNT-A uptake at the motor nerve terminals in animal models
[55]. ES is the most frequently studied adjunct therapy to BoNT-A
injection in humans [1]. Several studies reported that ES enhanced
the effect of BoNT-A, but the best ES procedure to couple with
BoNT-A for spasticity lacks agreement [1]. In particular, a cohort
study of 12 patients (PEDro score 4/10) found that in muscles
injected with BoNT-A, the compound muscle action potential
might be reduced more with low-frequency (4 Hz) than high-
frequency (25 Hz) ES [56]. Furthermore, a pilot study of
20 individuals (PEDro score 5/10) observed that ES of the injected
muscles delivered immediately after BoNT-A treatment might be
more effective than delayed ES on boosting BoNT-A action.
[57]. The authors explained their findings according to the
internalization process of BoNT-A, described to rapidly occur after
BoNT-A administration [57].
Also, functional electrical stimulation (FES) was investigated as
adjunct therapy to BoNT-A treatment. In particular, a preliminary
investigation of 18 patients (PEDro score 6/10) found improve-
ments in the walking speed of stroke patients with a spastic drop
foot treated with BoNT-A plus FES [58]. However, an RCT of
23 individuals (PEDro score 6/10) reported no gains in hand grasp
function with cyclic FES combined with OnabotulinumtoxinA in
patients with chronic spastic hemiparesis [58]. More recently, an
open-label, prospective clinical trial of 15 patients observed that
task-orientated therapy with electromyography-controlled FES
after BoNT-A injection effectively reduced spasticity and improved
upper-limb motor function in patients with spastic paresis [59].
3.5.5. Transcutaneous electrical nerve stimulation (TENS)
TENS may have 2 different effects (production of b-endorphin
or gate control effect) depending on the frequency (5 vs 80–
100 Hz). The antispastic effect of TENS has been hypothesized to
relate to the production of b-endorphins, which may decrease the
excitability of the motor neurons and (based on the gate control
theory) cause a reduction in nociceptive inputs [60]. Furthermore,
TENS has been suggested to facilitate cortical synaptic reorganiza-
tion and motor output by increasing sensory input due to
stimulation by larger-diameter A a,b fibers [60].
For patients with stroke, the recent literature recommends the
use of TENS to reduce spasticity, improve static balance and
increase walking speed because of its low cost, ease of use, and lack
of adverse reactions [61]. From a clinical viewpoint, comparison
with other spasticity interventions suggests that TENS is equiva-
lent to or better than oral baclofen and task-related training,
equivalent or inferior to exercise, and superior to cryotherapy [1].
4. Discussion
Patients with spasticity are disabled by 3main features: paresis
(reduced voluntary recruitment of skeletal motor units due to a
disruption of central voluntary motor command as a consequence
of upper motor-neuron disorders), soft tissue contracture and
muscle overactivity [62]. BoNT-A reduces muscle overactivity by
acting in the cytosol of nerve endings and inhibiting the release of
acetylcholine at neuromuscular junctions (it cleaves the 25 kDa
synaptosomal-associated protein, which is required for vesicledocking and, consequently, neurotransmitter release [63]). Cur-
rently, a number of adjuvant (rehabilitation) treatments have been
proposed to be combined with BoNT-A to potentiate its effect
(boosting or combined ‘‘neurological’’ effect) and reduce soft-
tissue contracture (non-neurological, rheological, effect).
Adhesive taping was found to effectively improve the BoNT-A
effect in the upper and lower limb in terms of spasticity, disability
and muscle activity [13–16]. However, from a daily practice
viewpoint, it might be difficult to apply (costly and time-
consuming), especially for outpatients (daily checking might
reduce compliance). With regard to (serial) casting, progressively
increasing stretch of the spasticmusclemight be useful despite the
few high-quality studies [18–25]. From a clinical perspective,
casting might be complicated in patients with sensory deficit (risk
of pressure sores). Finally, there is level 1 evidence that casting is
better than taping and taping is better than stretching for
outcomes including the MAS, ROM and gait [1]. Conversely,
consensus is lacking on taping and casting duration (days of
application), timing (early or delayed application), target (most
appropriate for upper or lower limbs or functional or non-
functional limbs) and material (kinesiotaping or wearable casts).
For physical modalities to combine with BoNT-A for treating
limb spasticity, a recent systematic review showed level 1 evidence
that ESWT is better than ES for some post-injection outcomes
including the MAS, spasm frequency and pain [1]. Furthermore, ES
of the injected muscles had a boosting effect on BoNT-A injection
[1,55–57]. From a clinical point of view, although the best ES
protocol has not been defined, it should include the lowest number
of sessions as possible (to improve compliance) and in linewith the
internalization process of BoNT-A (which has been reported to
occur rapidly after injection) [64]. In addition, there is level 2b
evidence that whole-body VT might be useful in reducing leg
muscle spasticity of patientswith cerebral palsy [45]. However, the
current literature overview found no study investigating BoNT-A
plus TENS [58]. Furthermore, to the best of our knowledge, we have
no evidence supporting the use of US as an adjuvant approach to
enhance the effects of BoNT-A treatment [8].
Unfortunately, the most appropriate adjuvant treatment
protocol after BoNT-A injection has not been defined, probably
because it should be based on the quality of evidence (which is
affected by the great variability of methods, study designs,
different populations/spasticity etiology, sample size, intervention
protocols, and outcomes considered, as shown in the current
literature overview) but also on several clinical and organizational
issues such as the goal to achieve, timing, setting, cost and
duration. Future research should focus on investigating the most
appropriate post-injection treatment protocol for each goal.
Funding
This research did not receive any specific grant from funding
agencies in the public, commercial, or not-for-profit sectors.
Disclosure of interest
The authors declare that they have no competing interest.
References
[1] Mills PB, Finlayson H, Sudol M, O’Connor R. Systematic review of adjunct
therapies to improve outcomes following botulinum toxin injection for treat-
ment of limb spasticity. Clin Rehabil 2016;30:537–48.
[2] Lance JW. The control of muscle tone, reflexes and movement: Robert War-
tenberg lecture. Neurology 1980;30:1303–13.
[3] Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al.
Practice guideline update summary: botulinum neurotoxin for the treatment
of blepharospasm, cervical dystonia, adult spasticity, and headache: report of
A. Picelli et al. / Annals of Physical and Rehabilitation Medicine 62 (2019) 291–296 295the guideline development subcommittee of the American Academy of Neu-
rology. Neurology 2016;86:1818–26.
[4] Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, et al.
European consensus table on the use of botulinum toxin type A in adult
spasticity. J Rehabil Med 2009;41:13–25.
[5] Smania N, Colosimo C, Bentivoglio AR, Sandrini G, Picelli A. Use of botulinum
toxin type A in the management of patients with neurological disorders: a
national survey. Funct Neurol 2013;28:253–8.
[6] Franceschini M, Iocco M, Molteni F, Smania N, Santamato A, Italian Spasticity
Study Group. Management of stroke patients submitted to botulinum toxin
type A therapy: a Delphi survey of an Italian expert panel of specialist injectors.
Eur J Phys Rehabil Med 2014;50:525–33.
[7] Khan F, Amatya B, Bensmail D, Yelnik A. Non-pharmacological interventions
for spasticity in adults: an overview of systematic reviews. Ann Phys Rehabil
Med 2017. http://dx.doi.org/10.1016/j.rehab.2017.10.001 [pii: S1877-
0657(17)30415-3 (Epub ahead of print) Review. PubMed PMID: 29042299.
[8] Smania N, Picelli A,Munari D, Geroin C, Ianes P,Waldner A, et al. Rehabilitation
procedures in the management of spasticity. Eur J Phys Rehabil Med
2010;46:423–38.
[9] Picelli A, Bacciga M, Melotti C, La Marchina E, Verzini E, Ferrari F, et al.
Combined effects of robot-assisted gait training and botulinum toxin type A
on spastic equinus foot in patients with chronic stroke: a pilot, single blind,
randomized controlled trial. Eur J Phys Rehabil Med 2016;52:759–66.
[10] Bovend’Eerdt TJ, Newman M, Barker K, Dawes H, Minelli C, Wade DT. The
effects of stretching in spasticity: a systematic review. Arch Phys Med Rehabil
2008;89:1395–406.
[11] Ryan ED, Beck TW, Herda TJ, Hull HR, Hartman MJ, Costa PB, et al. The time
course of musculotendinous stiffness responses following different durations
of passive stretching. J Orthop Sports Phys Ther 2008;38:632–9.
[12] Harvey LA, Katalinic OM, Herbert RD, Moseley AM, Lannin NA, Schurr K.
Stretch for the treatment and prevention of contractures. Cochrane Database
Syst Rev 2017;1. CD007455.
[13] Carda S, Molteni F. Taping versus electrical stimulation after botulinum toxin
type A injection for wrist and finger spasticity. A case-control study. Clin
Rehabil 2005;19:621–6.
[14] Santamato A, Micello MF, Panza F, Fortunato F, Picelli A, Smania N, et al.
Adhesive taping vs. daily manual muscle stretching and splinting after botu-
linum toxin type A injection for wrist and fingers spastic overactivity in stroke
patients: a randomized controlled trial. Clin Rehabil 2015;29:50–8.
[15] Reiter F, Danni M, Lagalla G, Ceravolo G, Provinciali L. Low-dose botulinum
toxin with ankle taping for the treatment of spastic equinovarus foot after
stroke. Arch Phys Med Rehabil 1998;79:532–5.
[16] Baricich A, Carda S, Bertoni M, Maderna L, Cisari C. A single-blinded, random-
ized pilot study of botulinum toxin type A combined with non-pharmacologi-
cal treatment for spastic foot. J Rehabil Med 2008;40:870–2.
[17] Karadag-Saygi E, Cubukcu-Aydoseli K, Kablan N, Ofluoglu D. The role of
kinesiotaping combined with botulinum toxin to reduce plantar flexors spas-
ticity after stroke. Top Stroke Rehabil 2010;17:318–22.
[18] Tardieu G, Tardieu C, Colbeau-Justin P, Lespargot A. Muscle hypoextensibility
in children with cerebral palsy: II. Therapeutic implications. Arch Phys Med
Rehabil 1982;63:103–7.
[19] Lannin NA, Novak I, Cusick A. A systematic review of upper extremity casting
for children and adults with central nervous system motor disorders. Clin
Rehabil 2007;21:963–76.
[20] Stoeckmann T. Casting for the person with spasticity. Top Stroke Rehabil
2001;8:27–35.
[21] Singer BJ, Dunne JW, Singer KP, Jegasothy GM, Allison GT. Non-surgical
management of ankle contracture following acquired brain injury. Disabil
Rehabil 2004;26:335–45.
[22] Newman CJ, Kennedy A,WalshM, O’Brien T, Lynch B, Hensey O. A pilot study of
delayed versus immediate serial-casting after botulinum toxin injection for
partially reducible spastic equinus. J Pediatr Orthoped 2007;27:882–5.
[23] Farina S, Migliorini C, Gandolfi M, Bertolasi L, Casarotto M, Manganotti P, et al.
Combined effects of botulinum toxin and casting treatments on lower limb
spasticity after stroke. Funct Neurol 2008;23:87–91.
[24] Yas¸ar E, Tok F, Safaz I, Balaban B, Yilmaz B, Alaca R. The efficacy of serial casting
after botulinum toxin type A injection in improving equinovarus deformity in
patients with chronic stroke. Brain Inj 2010;24:736–9.
[25] Carda S, Invernizzi M, Baricich A, Cisari C. Casting, taping or stretching after
botulinum toxin type A for spastic equinus foot: a single-blind randomized
trial on adult stroke patients. Clin Rehabil 2011;25:1119–27.
[26] Fess EE. A history of splinting: to understand the present, view the past. J Hand
Ther 2002;15:97–132.
[27] Cakar E, Durmus O, Tekin L, Dincer U, Kiralp MZ. The ankle-foot orthosis
improves balance and reduces fall risk of chronic spastic hemiparetic patients.
Eur J Phys Rehabil Med 2010;46:363–8.
[28] Buckon CE, Thomas SS, Jakobson-Huston S, Sussman M, Aiona M. Comparison
of three ankle-foot orthosis configurations for children with spastic hemiple-
gia. Dev Med Child Neurol 2001;43:371–8.
[29] Amini M, Shamili A, Frough B, Pashmdarfard M, Fallahzadeh Abarghouei A.
Combined effect of botulinum toxin and splinting on motor components and
function of people suffering a stroke. Med J Islam Repub Iran 2016;30:373.
[30] Pooyania S, Semenko B. Botulinum toxin type-A (BoNTA) and dynamic wrist-
hand orthoses versus orthoses alone for the treatment of spastic-paretic upper
extremity in chronic stroke patients. Open J Ther Rehabil 2014;2:12–8.[31] Ding XD, Zhang GB, Chen HX, Wang W, Song JH, Fu DG. Color doppler
ultrasound-guided botulinum toxin type A injection combined with an ankle
foot brace for treating lower limb spasticity after a stroke. Eur Rev Med
Pharmacol Sci 2015;19:406–11.
[32] Li TY, Chang CY, Chou YC, Chen LC, Chu HY, Chiang SL, et al. Effect of radial
shock wave therapy of spasticity of the upper limb in patients with chronic
stroke: a prospective, randomized, single blind, controlled trial. Medicine
(Baltimore) 2016;95:e3544.
[33] Dymarek R, Taradaj J, Rosin´czuk J. The effect of radial extracorporeal shock
wave stimulation on upper limb spasticity in chronic stroke patients: a single-
blind, randomized, placebo-controlled study. Ultrasound Med Biol
2016;42:1862–75.
[34] Santamato A, Notarnicola A, Panza F, Ranieri M, Micello MF, Manganotti P,
et al. SBOTE study: extracorporeal shock wave therapy versus electrical
stimulation after botulinum toxin type a injection for post-stroke spastici-
ty-a prospective randomized trial. Ultrasound Med Biol 2013;39:283–91.
[35] Picelli A, La Marchina E, Gajofatto F, Pontillo A, Vangelista A, Filippini R, et al.
Sonographic and clinical effects of botulinum toxin Type A combined with
extracorporeal shock wave therapy on spastic muscles of children with
cerebral palsy. Dev Neurorehabil 2017;20:160–4.
[36] Wu YT, Chang CN, Chen YM, Hu GC. Comparison of the effect of focused and
radial extracorporeal shockwaves on spastic equinus in patientswith stroke: a
randomized controlled trial. Eur J Phys Rehabil Med 2017;1–8. http://
dx.doi.org/10.23736/S1973-9087.17.04801-8.
[37] Ansari NN, Adelmanesh F, Naghdi S, Tabtabaei A. The effect of physiothera-
peutic ultrasound on muscle spasticity in patients with hemiplegia: a pilot
study. Electromyogr Clin Neurophysiol 2006;46:247–52.
[38] Ansari NN, Naghdi S, Bagheri H, Ghassabi H. Therapeutic ultrasound in the
treatment of ankle plantarflexor spasticity in a unilateral stroke population: a
randomized, single-blind, placebo-controlled trial. Electromyogr Clin Neuro-
physiol 2007;47:137–43.
[39] Gracies JM. Physical modalities other than stretch in spastic hypertonia. Phys
Med Rehabil Clin N Am 2001;12:769–92.
[40] Ansari NN, Naghdi S, Hasson S, Rastgoo M. Efficacy of therapeutic ultrasound
and infrared in the management of muscle spasticity. Brain Inj 2009;23:632–
8.
[41] Sahin N, Ugurlu H, Karahan AY. Efficacy of therapeutic ultrasound in the
treatment of spasticity: a randomized controlled study. NeuroRehabilitation
2011;29:61–6.
[42] Picelli A, Dambruoso F, BronzatoM, BarausseM, GandolfiM, Smania N. Efficacy
of therapeutic ultrasound and transcutaneous electrical nerve stimulation
compared with botulinum toxin type A in the treatment of spastic equinus in
adults with chronic stroke: a pilot randomized controlled trial. Top Stroke
Rehabil 2014;21:S8–16.
[43] Nielsen J, Petersen N, Crone C. Changes in transmission across synapses of Ia
afferents in spastic patients. Brain 1995;118:995–1004.
[44] Rittweger J. Vibration as an exercise modality: how it may work, and what its
potential might be. Eur J Appl Physiol 2010;108:877–904.
[45] Huang M, Liao LR, Pang MY. Effects of whole body vibration on muscle
spasticity for people with central nervous system disorders: a systematic
review. Clin Rehabil 2017;31:23–33.
[46] ChengHY, Yu YC,WongAM, Tsai YS, Ju YY. Effects of an eight-weekwhole body
vibration on lower extremity muscle tone and function in children with
cerebral palsy. Res Dev Disabil 2015;38:256–61.
[47] Ashby P, Verrier M, Lightfoot E. Segmental reflex pathways in spinal shock and
spinal spasticity in man. J Neurol Neurosurg Psychiatry 1974;37:1352–60.
[48] Noma T, Matsumoto S, Etoh S, Shimodozono M, Kawahira K. Anti-spastic
effects of the direct application of vibratory stimuli to the spastic muscles of
hemiplegic limbs in post-stroke patients. Brain Inj 2009;23:623–31.
[49] Celletti C, Camerota F. Preliminary evidence of focal muscle vibration effects
on spasticity due to cerebral palsy in a small sample of Italian children. Clin Ter
2011;162:e125–8.
[50] Caliandro P, Celletti C, Padua L, Minciotti I, Russo G, Granata G, et al. Focal
muscle vibration in the treatment of upper limb spasticity: a pilot randomized
controlled trial in patients with chronic stroke. Arch Phys Med Rehabil
2012;93:1656–61.
[51] Sadeghi M, Sawatzky B. Effects of vibration on spasticity in individuals with
spinal cord injury: a scoping systematic review. Am J Phys Med Rehabil
2014;93:995–1007.
[52] Seo HG, Oh BM, Leigh JH, Chun C, Park C, Kim CH. Effect of focal muscle
vibration on calf muscle spasticity: a proof-of-concept study. PM R
2016;8:1083–9.
[53] Calabro` RS, Naro A, Russo M, Milardi D, Leo A, Filoni S, et al. Is two better than
one? Muscle vibration plus robotic rehabilitation to improve upper limb
spasticity and function: a pilot randomized controlled trial. PLoS One
2017;12. e0185936.
[54] Paoloni M, Giovannelli M,MangoneM, Leonardi L, Tavernese E, Di Pangrazio E,
et al. Does giving segmental muscle vibration alter the response to botulinum
toxin injections in the treatment of spasticity in people with multiple sclero-
sis? A single-blind randomized controlled trial. Clin Rehabil 2013;27:803–12.
[55] Hughes R, Whaler BC. Influence of nerve-ending activity and of drugs on the
rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin. J
Physiol 1962;160:221–33.
[56] Frasson E, Priori A, Ruzzante B, Didone` G, Bertolasi L. Nerve stimulation boosts
botulinum toxin action in spasticity. Mov Disord 2005;20:624–9.
A. Picelli et al. / Annals of Physical and Rehabilitation Medicine 62 (2019) 291–296296[57] Picelli A, Smania N, Storti I, Munari D, Fontana C, Fiaschi A, et al. Immediate
versus delayed electrical stimulation boosts botulinum toxin effect: a pilot
study. Mov Disord 2011;26:1784–5.
[58] Intiso D, Santamato A, Di Rienzo F. Effect of electrical stimulation as an adjunct
to botulinum toxin type A in the treatment of adult spasticity: a systematic
review. Disabil Rehabil 2017;39:2123–33.
[59] Tsuchiya M, Morita A, Hara Y. Effect of dual therapy with botulinum toxin a
injection and electromyography-controlled functional electrical stimulation on
active function in the spastic paretic hand. J Nippon Med Sch 2016;83:15–23.
[60] Ng SS, Hui-Chan CW. Does the use of TENS increase the effectiveness of
exercise for improving walking after stroke?. A randomized controlled clinical
trial. Clin Rehabil 2009;23:1093–103.[61] Lin S, Sun Q, Wang H, Xie G. Influence of transcutaneous electrical nerve
stimulation on spasticity, balance, and walking speed in stroke patients: a
systematic review and meta-analysis. J Rehabil Med 2018;50:3–7.
[62] Gracies JM. Pathophysiology of spastic paresis. I: paresis and soft tissue
changes. Muscle Nerve 2005;31:535–51.
[63] Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clin
Dermatol 2003;21:476–80.
[64] Grumelli C, Verderio C, Pozzi D, Rossetto O, Montecucco C, Matteoli M.
Internalization and mechanism of action of clostridial toxins in neurons.
Neurotoxicology 2005;26:761–7.
